Time from Diagnosis and Correlates of Health-Related Quality of Life among Young Adult Colorectal Cancer Survivors

Kimberly A. Miller(University of Southern California), Afsaneh Barzi(City Of Hope National Medical Center), Lauren Govaerts(University of Southern California), Joel Milam, Zhen Weng(University of Southern California), Heinz‐Josef Lenz(University of Southern California), Jonathan N. Kaslander(University of Southern California), David R. Freyer(University of Southern California), Julia Stal(Dana-Farber Cancer Institute), Priscilla Marìn(USC Norris Comprehensive Cancer Center), Phuong Gallagher(Army and Navy Club)
Cancers
August 11, 2021
10.3390/cancers13164045
Cited by 24

Related Papers

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
|JAMA|2017|891
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer
|JAMA Oncology|2016|722
Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|433